

## CLS - Rights issue outcome and coverage resumed

Redeye provides an update as we resume coverage after CLS' rights issue. We give our thoughts on the capital raising, news during 2023, and our view of the Q1 report. We adjust our model accordingly to the rights issue outcome and make some changes in our estimates due to the report. We had estimated a rights issue; however, the dilution effect was significantly larger than we previously anticipated. Therefore, we lower our fair value range, including a new base case of SEK0.4 (1.3).

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

**CLS - Rights issue outcome and coverage resumed**